Goncalves Marcus D, Dunne Richard F, Moore Amy C, Phillips Wendy, Heymsfield Steven B, Brown Justin C, Talbert Erin E, Janowitz Tobias
NYU Langone Health, New York, NY.
University of Rochester Medical Center, Rochester, NY.
JCO Oncol Pract. 2025 Jul;21(7):926-931. doi: 10.1200/OP-24-00781. Epub 2025 Jan 13.
Cachexia is a systemic wasting syndrome prevalent in patients with cancer that significantly affects quality of life, health care costs, and therapeutic outcomes. Despite its clinical importance, cachexia is rarely formally diagnosed. This deficiency presents a challenge for effective patient management and care, health care resource allocation, and the advancement of therapeutic approaches. Here, we highlight impedances to the diagnosis and coding of cachexia, including the absence of standardized therapy, a lack of incentives for accurate coding, and overlapping clinical features with other conditions. We differentiate cachexia from related conditions like unintentional weight loss, sarcopenia, frailty, and protein-calorie malnutrition, outlining their distinct clinical features and inter-relations. We propose an approach to enhance diagnostic accuracy and coding for cachexia. This effort will enable better prevalence data, translation of mechanism-based therapy development, patient identification and stratification, and ultimately advanced diagnostics and US Food and Drug Administration-approved treatments for cachexia.
恶病质是一种在癌症患者中普遍存在的全身性消耗综合征,严重影响生活质量、医疗成本和治疗效果。尽管其具有临床重要性,但恶病质很少被正式诊断。这种不足给有效的患者管理与护理、医疗资源分配以及治疗方法的进步带来了挑战。在此,我们强调恶病质诊断和编码方面的阻碍,包括缺乏标准化治疗、缺乏准确编码的激励措施以及与其他病症重叠的临床特征。我们将恶病质与非故意体重减轻、肌肉减少症、虚弱和蛋白质 - 热量营养不良等相关病症区分开来,概述它们独特的临床特征和相互关系。我们提出一种提高恶病质诊断准确性和编码的方法。这一努力将有助于获得更好的患病率数据、基于机制的治疗开发转化、患者识别与分层,并最终实现恶病质的先进诊断和美国食品药品监督管理局批准的治疗方法。